Directorate Change

Smith & Nephew Plc

04 January 2024

 

4 January 2024                    

Board change

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that following completion of his nine-year tenure, Erik Engstrom stepped down from the Board on 31 December 2023.

The Board would like to thank Erik for his commitment and contribution to the Board and the Company.

Enquiries

Investors / Analysts Andrew Swift Smith+Nephew	[phone]
Media Charles Reynolds Smith+Nephew	[phone]
Susan Gilchrist / Ayesha Bharmal Brunswick	[phone]

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 19,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

END